

Product Data Sheet

Recombinant Human Vascular Endothelial Growth Factor - 165 (rhVEGF₁₆₅)

Description

| | |
|---------------------------|---|
| Source: | <i>E.coli</i> -derived, purified by proprietary chromatographic techniques Ala27-Arg191, Accession # P15692-4 |
| Structure/ Form: | Disulfide-linked homodimer, non-glycosylated, 165 amino acids |
| Predicted Molecular Mass: | 38 kDa (dimer) |

Specifications

| | |
|------------------|--|
| SDS-PAGE: | 39 kDa, non-reducing conditions; 21 kDa, reducing conditions |
| Activity: | Measured in a cell proliferation assay using HUVECs (human umbilical vein endothelial cells) [1]. The K _{0.5} is typically 5-20 pM. |
| Purity: | > 95 %, determined by SDS-PAGE |
| Endotoxin Level: | < 0.05 EU per 1 µg of the protein by the LAL method. |
| Formulation: | Lyophilized from a 0.2 µm filtered concentrated (100 µg/ml) solution in PBS buffer (pH 7.4). |

Preparation and Storage

| | |
|----------------------|---|
| Solubility: | It is recommended to reconstitute the lyophilized VEGF in sterile H ₂ O, which can be further dialyzed to other aqueous solutions. |
| Shipping: | The product is shipped at ambient temperature. Upon receipt store it immediately at the temperature recommended below. |
| Stability & Storage: | Please avoid freeze-thaw cycles. <ul style="list-style-type: none">• 2-8 °C: 4 weeks after reconstruction• -20 - -70 °C: 3 months after reconstruction• -20 - -70 °C: 12 months as supplied |

References:

- [1] K. Zurlinden, M. Laub, D.S. Dohle, K.P. Jennissen (2012), Immobilization and Controlled Release of Vascular (VEGF) and Bone Growth Factors (BMP-2) on Bone Replacement Materials, Biomed Tech (57). 989-992

For research use only.

Not for human use.